This study aims to evaluate the efficacy and safety of PD‐1/PD‐L1 inhibitors in treating small‐cell lung cancer (SCLC) and determine the role of PD‐1 monoclonal antibodies in improving patient outcomes. This evidence concerns the gene CD274 and small cell lung carcinoma.